Showing 2451-2460 of 5693 results for "".
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In
- Refractive Surgery Council Reports Strongest H1 Laser Vision Correction (LVC) Procedure Volume Growth in Nearly a Decadehttps://modernod.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/The Refractive Surgery Council (RSC) reported the strongest first half laser vision correction (LVC) procedure volume growth in nearly a decade. The 82 percent year-over-year growth, fueled by the strong quarter-over-quarter performance, resulted in 231,503 LASIK, SMILE and PRK procedures perform
- EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/EyePoint Pharmaceuticals announced today that the company expects to receive a 9-month extension on Dexycu’s pass-through payment status, which otherwise would expire on March 31, 2022. On July 19, 2021, CMS released its 2022 draft Hospital Outpatient Prospective
- NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx to Promote Prescription Avenovahttps://modernod.com/news/novabay-pharmaceuticals-partners-with-harrow-healths-imprimisrx-to-promote-prescription-avenova/2479378/NovaBay Pharmaceuticals announced it has partnered with ImprimisRx to promote prescription Avenova. ImprimisRx, a wholly owned subsidiary of Harrow Health, will provide NovaBay with national sales, marketing, and distribution support for its FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bo
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom